The Elite Universal Test
Bank: Kaplan
Pharmacology
Integrated Mastery
(v10.0)
PART 0: THE NAVIGATOR
● PART I: THE PRIMER
○ The Hook
○ The "Critical Axioms" Cheat Sheet: 2026/2027 Standards
● PART II: THE ELITE TEST BANK
○ Tier 1 (Questions 1–28) - Foundational Syntax & Application: Testing "Hard
Deck" definitions, core regulatory mechanisms, high-alert ISMP protocols, and
pharmacokinetic absolutes.
○ Tier 2 (Questions 29–58) - Complex Application & Simulation: Dynamic clinical
variables, 2026 ADA/KDIGO/AHA guideline application, drug-drug interactions, and
immediate mitigation strategies.
○ Tier 3 (Questions 59–88) - Grandmaster Synthesis: High-stakes, multi-system
pharmacological crises requiring intersecting logic, novel agent integration, and
emergency reversal protocols to avert patient failure.
PART I: THE PRIMER
The contemporary pharmacological landscape demands anticipatory clinical judgment to
intercept physiological crises before they manifest. Mastering this elite test bank forges
practitioners capable of synthesizing high-stakes polypharmacy, navigating multi-system
failures, and applying the most current 2026/2027 global clinical guidelines directly to elite
patient care.
The "Critical Axioms" Cheat Sheet: 2026/2027 Standards
To survive the modern clinical environment, rote memorization must be replaced with
mechanistic logic. The following table codifies the absolute regulatory and pharmacological
shifts defining top-tier practice.
,Clinical Domain Legacy Standard 2026/2027 Elite Rationale / Mechanism
(Pre-2025) Standard
IV Push Safety Bedside dilution in Strictly Prohibited. Eliminates bedside
saline flush syringes Must use contamination,
permitted. Ready-to-Administer wrong-drug selection,
(RTA) syringes. and inexact dosing
concentrations.
Schizophrenia Reliance on D2 Integration of Cobenfy Eliminates
dopamine blockade (xanomeline/trospium) extrapyramidal
(e.g., haloperidol, via muscarinic symptoms; introduces
risperidone). agonism. hard stops for urinary
retention and hepatic
impairment.
Obesity/T2DM Strict fasting Foundayo (orforglipron) Small-molecule,
constraints for oral allows administration non-peptide GLP-1
GLP-1s (e.g., any time, without receptor agonists
Rybelsus). food/water restrictions. bypass gastric
absorption limitations.
Heart Failure Sequential, slow Rapid, forced-titration Maximizes
titration of ACEi/BB of the "Four Pillars" neurohormonal
based on symptoms. (ARNI, BB, MRA, blockade to prevent
SGLT2i). mortality and
myocardial remodeling.
COPD Biologics Escalation to chronic Dupilumab initiated for Directly intercepts
oral corticosteroids. blood eosinophils ≥ 300 IL-4/IL-13 type-2
cells/μL. inflammation pathways,
sparing bone density
and immunity.
RSV Prophylaxis Palivizumab monthly Nirsevimab (<5 kg = 50 Long-acting
injections for neonates. mg; ≥5 kg = 100 mg) monoclonal antibodies
OR maternal Abrysvo provide season-long
(32-36 weeks). passive immunity with a
single dose.
PART II: THE ELITE TEST BANK
Tier 1: Foundational Syntax & Application
Q1: A nurse prepares to administer a newly prescribed intravenous medication. According to the
ISMP 2026-2027 Targeted Medication Safety Best Practices, which action regarding IV push
administration is STRICTLY PROHIBITED? A) Utilizing a ready-to-administer syringe provided
directly by the pharmacy compounding center. B) Administering the medication via an infusion
pump with dose error-reduction systems (DERS) when slow administration is required. C)
Diluting the medication into a prefilled sodium chloride flush syringe immediately prior to
administration. D) Preparing the medication immediately before administration to prevent
prolonged room-temperature exposure.
● The Answer: C (Diluting the medication into a prefilled sodium chloride flush syringe
, immediately prior to administration.)
● Distractor Analysis: * A is incorrect: ISMP explicitly mandates optimizing the use of RTA
products. * B is incorrect: Infusion pumps with DERS are recommended when manual
push rates are impractical (e.g., >5 minutes). * D is incorrect: Preparing medications just
prior to administration is a standard safety practice.
The Mentor's Analysis: Bedside manipulation of intravenous agents introduces catastrophic
risks for dosing errors and contamination. When facing IV push administration, the immediate
priority is preserving the sterile, standardized concentration. By utilizing pharmacy-prepared
RTA syringes, you bypass the common trap of rogue bedside dilution. Professional/Academic
Intuition: Never use a saline flush syringe as a dilution vessel.
Q2: A provider orders daily oral methotrexate for a patient with rheumatoid arthritis. Based on
ISMP high-alert protocols, which action is the IMMEDIATE requirement? A) Administer the
medication precisely at the same time every morning to ensure steady-state pharmacokinetics.
B) Require a hard stop verification to confirm an oncologic indication, as daily dosing is fatal for
rheumatoid arthritis. C) Crush the medication and administer it with applesauce to prevent
gastrointestinal mucosal damage. D) Draw a baseline absolute neutrophil count (ANC) and
administer the first dose immediately.
● The Answer: B (Require a hard stop verification to confirm an oncologic indication, as
daily dosing is fatal for rheumatoid arthritis.)
● Distractor Analysis: * A is incorrect: Daily dosing of non-oncologic methotrexate causes
fatal bone marrow suppression and hepatic necrosis. * C is incorrect: Crushing cytotoxic
agents exposes the clinician to aerosolized teratogens and does not prevent mucosal
damage. * D is incorrect: Administering a daily dose for an autoimmune indication is a
catastrophic error.
The Mentor's Analysis: Accidental daily dosing of methotrexate intended for weekly
administration is a primary cause of preventable fatality. When facing a daily oral methotrexate
order, the immediate priority is verifying an oncologic indication via a hard stop. By utilizing
systemic prescribing safeguards, you bypass the common trap of administering a lethal
immunosuppressive overdose. Professional/Academic Intuition: For autoimmune conditions,
methotrexate is a weekly marathon; daily administration is a fatal sprint.
Q3: A patient is newly prescribed Cobenfy (xanomeline and trospium chloride) for
schizophrenia. During the baseline assessment, which finding represents an ABSOLUTE
CONTRAINDICATION to this therapy? A) A history of severe extrapyramidal symptoms from
haloperidol. B) A documented diagnosis of benign prostatic hyperplasia with chronic urinary
retention. C) A baseline resting heart rate of 68 beats per minute. D) A history of diet-controlled
type 2 diabetes mellitus.
● The Answer: B (A documented diagnosis of benign prostatic hyperplasia with chronic
urinary retention.)
● Distractor Analysis: * A is incorrect: Cobenfy lacks D2 blockade, making it ideal for
patients with prior extrapyramidal symptoms. * C is incorrect: A normal heart rate is not a
contraindication, though the drug can cause tachycardia. * D is incorrect: Unlike atypical
antipsychotics, Cobenfy lacks warnings for metabolic syndrome or weight gain.
The Mentor's Analysis: Cobenfy relies on muscarinic receptor agonism centrally, but uses
trospium (a peripheral anticholinergic) to block systemic cholinergic side effects. When facing a
Cobenfy prescription, the immediate priority is assessing cholinergic and anticholinergic
vulnerabilities. By utilizing baseline urologic screening, you bypass the common trap of
precipitating acute renal injury via urinary retention. Professional/Academic Intuition:
Cholinergic psychiatric drugs demand rigorous urologic and hepatic clearance; trospium
, paralyses the bladder.
Q4: An adult patient with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) is
initiated on Myqorzo (aficamten). According to the FDA REMS program, what is the MOST
CRITICAL ongoing monitoring parameter? A) Weekly absolute neutrophil counts to monitor for
agranulocytosis. B) Serial echocardiograms to ensure the left ventricular ejection fraction
remains ≥ 50%. C) Daily fasting blood glucose to monitor for profound hypoglycemia. D) Routine
pulmonary function tests to assess for drug-induced interstitial lung disease.
● The Answer: B (Serial echocardiograms to ensure the left ventricular ejection fraction
remains ≥ 50%.)
● Distractor Analysis: * A is incorrect: Cardiac myosin inhibitors do not typically cause
agranulocytosis. * C is incorrect: Aficamten does not impact glycemic control. * D is
incorrect: Interstitial lung disease is not a recognized complication of this therapy.
The Mentor's Analysis: Aficamten reduces cardiac contractility to relieve outflow tract
obstruction, carrying an inherent risk of inducing heart failure due to systolic dysfunction. When
managing cardiac myosin inhibitors, the immediate priority is preserving systolic function. By
utilizing serial echocardiography through the REMS program , you bypass the common trap of
inducing iatrogenic heart failure. Professional/Academic Intuition: If LVEF drops below 40% on
a myosin inhibitor, the drug must be interrupted immediately.
Q5: A patient with obesity is prescribed Foundayo (orforglipron) for chronic weight management.
How should the nurse instruct the patient to administer this medication? A) Take the pill exactly
30 minutes before the first food or beverage of the day, with no more than 4 ounces of water. B)
Take the pill once daily at any time of day, without restrictions on food or water intake. C)
Administer the medication via subcutaneous injection into the abdomen once weekly. D) Take
the medication exclusively at bedtime to mitigate severe gastrointestinal side effects.
● The Answer: B (Take the pill once daily at any time of day, without restrictions on food or
water intake.)
● Distractor Analysis: * A is incorrect: This is the strict administration protocol for oral
semaglutide (Rybelsus), not orforglipron. * C is incorrect: Foundayo is an oral formulation,
not an injectable. * D is incorrect: There is no requirement or specific benefit to bedtime
dosing for this agent.
The Mentor's Analysis: Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist,
allowing it to bypass the strict absorption constraints of oral peptides. When educating patients
on Foundayo, the immediate priority is emphasizing its dosing flexibility. By utilizing its lack of
food/water restrictions, you bypass the common trap of therapy abandonment due to rigid
morning fasting rules. Professional/Academic Intuition: Small-molecule GLP-1 pills separate
the efficacy of incretins from the burden of fasting.
Q6: According to the 2026 GOLD Guidelines, a patient with chronic obstructive pulmonary
disease (COPD) experiencing persistent exacerbations is a candidate for dupilumab IF which
baseline biomarker is present? A) A serum alpha-1 antitrypsin level below 11 μmol/L. B) A blood
eosinophil count of ≥ 300 cells/μL. C) A fractional exhaled nitric oxide (FeNO) level < 10 ppb. D)
A significantly elevated brain natriuretic peptide (BNP).
● The Answer: B (A blood eosinophil count of ≥ 300 cells/μL.)
● Distractor Analysis: * A is incorrect: Alpha-1 antitrypsin deficiency requires augmentation
therapy, not dupilumab. * C is incorrect: FeNO is a marker for asthma; dupilumab efficacy
in COPD is tied specifically to eosinophils. * D is incorrect: BNP assesses heart failure,
not type-2 airway inflammation.
The Mentor's Analysis: Dupilumab targets the IL-4/IL-13 pathway, effectively shutting down
type-2 inflammation in the lungs. When evaluating biologic eligibility in COPD, the immediate
Bank: Kaplan
Pharmacology
Integrated Mastery
(v10.0)
PART 0: THE NAVIGATOR
● PART I: THE PRIMER
○ The Hook
○ The "Critical Axioms" Cheat Sheet: 2026/2027 Standards
● PART II: THE ELITE TEST BANK
○ Tier 1 (Questions 1–28) - Foundational Syntax & Application: Testing "Hard
Deck" definitions, core regulatory mechanisms, high-alert ISMP protocols, and
pharmacokinetic absolutes.
○ Tier 2 (Questions 29–58) - Complex Application & Simulation: Dynamic clinical
variables, 2026 ADA/KDIGO/AHA guideline application, drug-drug interactions, and
immediate mitigation strategies.
○ Tier 3 (Questions 59–88) - Grandmaster Synthesis: High-stakes, multi-system
pharmacological crises requiring intersecting logic, novel agent integration, and
emergency reversal protocols to avert patient failure.
PART I: THE PRIMER
The contemporary pharmacological landscape demands anticipatory clinical judgment to
intercept physiological crises before they manifest. Mastering this elite test bank forges
practitioners capable of synthesizing high-stakes polypharmacy, navigating multi-system
failures, and applying the most current 2026/2027 global clinical guidelines directly to elite
patient care.
The "Critical Axioms" Cheat Sheet: 2026/2027 Standards
To survive the modern clinical environment, rote memorization must be replaced with
mechanistic logic. The following table codifies the absolute regulatory and pharmacological
shifts defining top-tier practice.
,Clinical Domain Legacy Standard 2026/2027 Elite Rationale / Mechanism
(Pre-2025) Standard
IV Push Safety Bedside dilution in Strictly Prohibited. Eliminates bedside
saline flush syringes Must use contamination,
permitted. Ready-to-Administer wrong-drug selection,
(RTA) syringes. and inexact dosing
concentrations.
Schizophrenia Reliance on D2 Integration of Cobenfy Eliminates
dopamine blockade (xanomeline/trospium) extrapyramidal
(e.g., haloperidol, via muscarinic symptoms; introduces
risperidone). agonism. hard stops for urinary
retention and hepatic
impairment.
Obesity/T2DM Strict fasting Foundayo (orforglipron) Small-molecule,
constraints for oral allows administration non-peptide GLP-1
GLP-1s (e.g., any time, without receptor agonists
Rybelsus). food/water restrictions. bypass gastric
absorption limitations.
Heart Failure Sequential, slow Rapid, forced-titration Maximizes
titration of ACEi/BB of the "Four Pillars" neurohormonal
based on symptoms. (ARNI, BB, MRA, blockade to prevent
SGLT2i). mortality and
myocardial remodeling.
COPD Biologics Escalation to chronic Dupilumab initiated for Directly intercepts
oral corticosteroids. blood eosinophils ≥ 300 IL-4/IL-13 type-2
cells/μL. inflammation pathways,
sparing bone density
and immunity.
RSV Prophylaxis Palivizumab monthly Nirsevimab (<5 kg = 50 Long-acting
injections for neonates. mg; ≥5 kg = 100 mg) monoclonal antibodies
OR maternal Abrysvo provide season-long
(32-36 weeks). passive immunity with a
single dose.
PART II: THE ELITE TEST BANK
Tier 1: Foundational Syntax & Application
Q1: A nurse prepares to administer a newly prescribed intravenous medication. According to the
ISMP 2026-2027 Targeted Medication Safety Best Practices, which action regarding IV push
administration is STRICTLY PROHIBITED? A) Utilizing a ready-to-administer syringe provided
directly by the pharmacy compounding center. B) Administering the medication via an infusion
pump with dose error-reduction systems (DERS) when slow administration is required. C)
Diluting the medication into a prefilled sodium chloride flush syringe immediately prior to
administration. D) Preparing the medication immediately before administration to prevent
prolonged room-temperature exposure.
● The Answer: C (Diluting the medication into a prefilled sodium chloride flush syringe
, immediately prior to administration.)
● Distractor Analysis: * A is incorrect: ISMP explicitly mandates optimizing the use of RTA
products. * B is incorrect: Infusion pumps with DERS are recommended when manual
push rates are impractical (e.g., >5 minutes). * D is incorrect: Preparing medications just
prior to administration is a standard safety practice.
The Mentor's Analysis: Bedside manipulation of intravenous agents introduces catastrophic
risks for dosing errors and contamination. When facing IV push administration, the immediate
priority is preserving the sterile, standardized concentration. By utilizing pharmacy-prepared
RTA syringes, you bypass the common trap of rogue bedside dilution. Professional/Academic
Intuition: Never use a saline flush syringe as a dilution vessel.
Q2: A provider orders daily oral methotrexate for a patient with rheumatoid arthritis. Based on
ISMP high-alert protocols, which action is the IMMEDIATE requirement? A) Administer the
medication precisely at the same time every morning to ensure steady-state pharmacokinetics.
B) Require a hard stop verification to confirm an oncologic indication, as daily dosing is fatal for
rheumatoid arthritis. C) Crush the medication and administer it with applesauce to prevent
gastrointestinal mucosal damage. D) Draw a baseline absolute neutrophil count (ANC) and
administer the first dose immediately.
● The Answer: B (Require a hard stop verification to confirm an oncologic indication, as
daily dosing is fatal for rheumatoid arthritis.)
● Distractor Analysis: * A is incorrect: Daily dosing of non-oncologic methotrexate causes
fatal bone marrow suppression and hepatic necrosis. * C is incorrect: Crushing cytotoxic
agents exposes the clinician to aerosolized teratogens and does not prevent mucosal
damage. * D is incorrect: Administering a daily dose for an autoimmune indication is a
catastrophic error.
The Mentor's Analysis: Accidental daily dosing of methotrexate intended for weekly
administration is a primary cause of preventable fatality. When facing a daily oral methotrexate
order, the immediate priority is verifying an oncologic indication via a hard stop. By utilizing
systemic prescribing safeguards, you bypass the common trap of administering a lethal
immunosuppressive overdose. Professional/Academic Intuition: For autoimmune conditions,
methotrexate is a weekly marathon; daily administration is a fatal sprint.
Q3: A patient is newly prescribed Cobenfy (xanomeline and trospium chloride) for
schizophrenia. During the baseline assessment, which finding represents an ABSOLUTE
CONTRAINDICATION to this therapy? A) A history of severe extrapyramidal symptoms from
haloperidol. B) A documented diagnosis of benign prostatic hyperplasia with chronic urinary
retention. C) A baseline resting heart rate of 68 beats per minute. D) A history of diet-controlled
type 2 diabetes mellitus.
● The Answer: B (A documented diagnosis of benign prostatic hyperplasia with chronic
urinary retention.)
● Distractor Analysis: * A is incorrect: Cobenfy lacks D2 blockade, making it ideal for
patients with prior extrapyramidal symptoms. * C is incorrect: A normal heart rate is not a
contraindication, though the drug can cause tachycardia. * D is incorrect: Unlike atypical
antipsychotics, Cobenfy lacks warnings for metabolic syndrome or weight gain.
The Mentor's Analysis: Cobenfy relies on muscarinic receptor agonism centrally, but uses
trospium (a peripheral anticholinergic) to block systemic cholinergic side effects. When facing a
Cobenfy prescription, the immediate priority is assessing cholinergic and anticholinergic
vulnerabilities. By utilizing baseline urologic screening, you bypass the common trap of
precipitating acute renal injury via urinary retention. Professional/Academic Intuition:
Cholinergic psychiatric drugs demand rigorous urologic and hepatic clearance; trospium
, paralyses the bladder.
Q4: An adult patient with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) is
initiated on Myqorzo (aficamten). According to the FDA REMS program, what is the MOST
CRITICAL ongoing monitoring parameter? A) Weekly absolute neutrophil counts to monitor for
agranulocytosis. B) Serial echocardiograms to ensure the left ventricular ejection fraction
remains ≥ 50%. C) Daily fasting blood glucose to monitor for profound hypoglycemia. D) Routine
pulmonary function tests to assess for drug-induced interstitial lung disease.
● The Answer: B (Serial echocardiograms to ensure the left ventricular ejection fraction
remains ≥ 50%.)
● Distractor Analysis: * A is incorrect: Cardiac myosin inhibitors do not typically cause
agranulocytosis. * C is incorrect: Aficamten does not impact glycemic control. * D is
incorrect: Interstitial lung disease is not a recognized complication of this therapy.
The Mentor's Analysis: Aficamten reduces cardiac contractility to relieve outflow tract
obstruction, carrying an inherent risk of inducing heart failure due to systolic dysfunction. When
managing cardiac myosin inhibitors, the immediate priority is preserving systolic function. By
utilizing serial echocardiography through the REMS program , you bypass the common trap of
inducing iatrogenic heart failure. Professional/Academic Intuition: If LVEF drops below 40% on
a myosin inhibitor, the drug must be interrupted immediately.
Q5: A patient with obesity is prescribed Foundayo (orforglipron) for chronic weight management.
How should the nurse instruct the patient to administer this medication? A) Take the pill exactly
30 minutes before the first food or beverage of the day, with no more than 4 ounces of water. B)
Take the pill once daily at any time of day, without restrictions on food or water intake. C)
Administer the medication via subcutaneous injection into the abdomen once weekly. D) Take
the medication exclusively at bedtime to mitigate severe gastrointestinal side effects.
● The Answer: B (Take the pill once daily at any time of day, without restrictions on food or
water intake.)
● Distractor Analysis: * A is incorrect: This is the strict administration protocol for oral
semaglutide (Rybelsus), not orforglipron. * C is incorrect: Foundayo is an oral formulation,
not an injectable. * D is incorrect: There is no requirement or specific benefit to bedtime
dosing for this agent.
The Mentor's Analysis: Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist,
allowing it to bypass the strict absorption constraints of oral peptides. When educating patients
on Foundayo, the immediate priority is emphasizing its dosing flexibility. By utilizing its lack of
food/water restrictions, you bypass the common trap of therapy abandonment due to rigid
morning fasting rules. Professional/Academic Intuition: Small-molecule GLP-1 pills separate
the efficacy of incretins from the burden of fasting.
Q6: According to the 2026 GOLD Guidelines, a patient with chronic obstructive pulmonary
disease (COPD) experiencing persistent exacerbations is a candidate for dupilumab IF which
baseline biomarker is present? A) A serum alpha-1 antitrypsin level below 11 μmol/L. B) A blood
eosinophil count of ≥ 300 cells/μL. C) A fractional exhaled nitric oxide (FeNO) level < 10 ppb. D)
A significantly elevated brain natriuretic peptide (BNP).
● The Answer: B (A blood eosinophil count of ≥ 300 cells/μL.)
● Distractor Analysis: * A is incorrect: Alpha-1 antitrypsin deficiency requires augmentation
therapy, not dupilumab. * C is incorrect: FeNO is a marker for asthma; dupilumab efficacy
in COPD is tied specifically to eosinophils. * D is incorrect: BNP assesses heart failure,
not type-2 airway inflammation.
The Mentor's Analysis: Dupilumab targets the IL-4/IL-13 pathway, effectively shutting down
type-2 inflammation in the lungs. When evaluating biologic eligibility in COPD, the immediate
